VEGFA and chronic kidney disease: In our CKD model, at 6 weeks after injection of MSC-CM or MSC-NCM we found no differences in the numbers of apoptotic and proliferating cells, nor in the presence of VEGF in the kidney, however, we cannot exclude that anti-apoptotic, mitogenic or VEGF effects have occurred in an earlier stage.